DaVita Inc. (NYSE:DVA) Shares Sold by Sei Investments Co.

Sei Investments Co. reduced its stake in DaVita Inc. (NYSE:DVA) by 18.8% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 34,061 shares of the company’s stock after selling 7,891 shares during the quarter. Sei Investments Co.’s holdings in DaVita were worth $4,719,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its holdings in DaVita by 196.9% during the 1st quarter. SG Americas Securities LLC now owns 29,733 shares of the company’s stock valued at $4,105,000 after acquiring an additional 19,719 shares during the period. Bessemer Group Inc. raised its position in shares of DaVita by 2,335.6% during the 1st quarter. Bessemer Group Inc. now owns 10,741 shares of the company’s stock worth $1,483,000 after acquiring an additional 10,300 shares in the last quarter. Forsta AP Fonden grew its stake in DaVita by 50.3% during the 1st quarter. Forsta AP Fonden now owns 23,600 shares of the company’s stock worth $3,258,000 after buying an additional 7,900 shares during the last quarter. Fox Hill Wealth Management grew its stake in DaVita by 138.4% during the 1st quarter. Fox Hill Wealth Management now owns 15,734 shares of the company’s stock worth $2,172,000 after buying an additional 9,135 shares during the last quarter. Finally, 8 Knots Management LLC purchased a new position in DaVita during the 4th quarter worth approximately $89,504,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Performance

Shares of DVA stock opened at $162.75 on Wednesday. DaVita Inc. has a 12-month low of $71.51 and a 12-month high of $166.04. The firm has a market capitalization of $13.65 billion, a price-to-earnings ratio of 18.49, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. The business has a 50 day simple moving average of $151.04 and a 200 day simple moving average of $142.52. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. The firm had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.15 billion. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period last year, the company posted $2.08 EPS. On average, equities research analysts anticipate that DaVita Inc. will post 9.99 EPS for the current year.

Insider Activity

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares in the company, valued at $12,137,038.31. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Joel Ackerman sold 64,029 shares of DaVita stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the transaction, the chief financial officer now owns 111,481 shares in the company, valued at $17,286,243.86. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 173,482 shares of company stock worth $27,387,069. 2.00% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

DVA has been the topic of several analyst reports. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. UBS Group boosted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Bank of America boosted their price target on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. TD Cowen upped their target price on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Finally, Truist Financial upped their target price on DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $157.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.